Director buys 70K Aldeyra Therapeutics (ALDX) shares at $1.40

Rhea-AI Filing Summary

Aldeyra Therapeutics director Richard Douglas bought more company stock in the open market. He acquired 70,000 shares of common stock in an open-market purchase at $1.40 per share. Following this transaction, he directly owns 195,000 shares, indicating a larger personal stake in Aldeyra Therapeutics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOUGLAS RICHARD

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		P		70,000	A	$1.4	195,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Richard Douglas	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aldeyra Therapeutics (ALDX) disclose?

Aldeyra Therapeutics disclosed that director Richard Douglas purchased 70,000 shares of common stock. The shares were bought in an open-market transaction, indicating he chose to increase his direct ownership in the company.

At what price did the Aldeyra Therapeutics director buy shares?

Richard Douglas bought 70,000 Aldeyra Therapeutics shares at $1.40 per share. The transaction was an open-market purchase, meaning he acquired the stock on the public market rather than through a grant or option exercise.

How many Aldeyra Therapeutics shares does Richard Douglas own after this trade?

After the transaction, Richard Douglas directly owns 195,000 shares of Aldeyra Therapeutics common stock. This figure includes the newly purchased 70,000 shares and represents his total direct holdings reported in the filing.

Was the Aldeyra Therapeutics (ALDX) insider transaction a purchase or sale?

The transaction was a purchase. Director Richard Douglas executed an open-market buy of 70,000 Aldeyra Therapeutics common shares, with the filing classifying the transaction direction as a buy rather than a sale or other disposition.

Is the Aldeyra Therapeutics insider transaction a direct or indirect holding?

The filing reports the holding as direct ownership. Richard Douglas is listed with direct ownership of 195,000 Aldeyra Therapeutics shares after the transaction, with no indirect ownership entity or special nature of ownership disclosed.